NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Stoke Therapeutics, Inc. (STOK) Stock Analysis

Stoke Therapeutics, Inc. (STOK) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

STOK

$29.81

−$0.18 (−0.60%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare STOK with… →

STOK Key Statistics

As of Sep 4, 2026
Trading
Open
$29.41
Previous Close
$29.99
Day's Range
29.15–30.03
52-Week Range
20.32–40.22
Volume
714.00K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.23
Valuation
Market Cap
$1.92B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
69.72
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.39
Financials (FY)
Revenue (FY)
$184.42M+404.50%
Net Income (FY)
−$6.89M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
64.53M
1-Year Return
+51.86%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
878.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

STOK Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−6.08%
2025+187.76%
2024+109.70%
2023−43.01%
2022−61.53%
2021−61.26%
2020+118.68%
2019 (partial year)+10.75%

As of September 4, 2026.

STOK Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$184.42M−$6.89M−3.7%
2024$36.56M−$88.98M−243.4%
2023$8.78M−$104.70M−1192.5%
2022$12.41M−$101.07M−814.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$184.42M—−$20.59M−$6.89M−3.7%
2024$36.56M—−$101.37M−$88.98M−243.4%
2023$8.78M—−$114.77M−$104.70M−1192.5%
2022$12.41M—−$104.36M−$101.07M−814.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

STOK Valuation vs Biotechnology Median

Median of 656 stocks
MetricSTOKBiotechnology medianvs median
P/S ratio69.7215.264.6x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Stoke Therapeutics, Inc. (STOK) is capitalised at $1.92B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 170 employees.

The 52-week range on file runs from $20.32 to $40.22. The most recent close on file for STOK is $29.81, dated September 4, 2026. That is −$0.18 (−0.60%) against the previous close. The latest close sits 46.7% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $184.42M. That is +404.50% against the prior fiscal year, when revenue was $36.56M. The same year closed with a net loss of $6.89M. Profit margin runs at 0%. Trailing earnings per share are −3.39.

Across the 4 fiscal years on file, revenue moves from $12.41M in 2022 to $184.42M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 69.72 times revenue. On price-to-sales that is 4.6 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at 1.23. Daily returns over the trailing 7 years annualize to a volatility of 79.76%. Over the trailing twelve months the price has returned +51.86%. Across 5 years the annualized return works out at +3.29%.

Growth & Income

The record shows no dividend for STOK.

2026 is still running; the price is −6.08% year to date. Across the complete calendar years on file, 2025 returned +187.76% and 2022 returned −61.53%. Of the 6 complete calendar years on file, 3 finished higher.

Peer Comparison

Stoke Therapeutics, Inc. (STOK) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Stoke Therapeutics, Inc. STOK $1.92B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Stoke Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Visit website →